Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic

Authors
Ben Jackson, Maciej F. Boni, Matthew J. Bull, ..., David L. Robertson, Oliver G. Pybus, Andrew Rambaut

Correspondence
ben.jackson@ed.ac.uk (B.J.), a.rambaut@ed.ac.uk (A.R.)

In brief
Sampling from late 2020 to early 2021 provides evidence for SARS-CoV-2 recombination and onward community transmission of recombinant viruses that inherited the spike region from the B.1.1.7 (alpha) variant.

Highlights
- We find evidence for recombination in SARS-CoV-2
- We identify eight clear recombination events, four of which lead to onward transmission
- Estimated breakpoints are consistent with coronavirus cellular replication dynamics
- Transmitted recombinants inherited the more-transmissible B.1.1.7 spike gene
Article

Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic

Ben Jackson, 1,11,* Maciej F. Boni, 2 Matthew J. Bull, 3 Amy Colleran, 4 Rachel M. Colquhoun, 1 Alistair C. Darby, 4 Sam Haldenby, 4 Verity Hill, 1 Anita Lucaci, 4 John T. McCrone, 4 Samuel M. Nicholls, 6 Áine O’Toole, 1 Nicole Pacchiarini, 3 Radoslaw Poplawski, 6 Emily Scher, 1 Flora Todd, 4 Hermione J. Webster, 4 Mark Whitehead, 4 Claudia Wierzbicki, 4 The COVID-19 Genomics UK (COG-UK) Consortium, 6 Nicholas J. Loman, 5 Thomas R. Connor, 3,7 David L. Robertson, 8 Oliver G. Pybus, 9,10 and Andrew Rambaut 1,*

1 Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK
2 Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA 16802, USA
3 Pathogen Genomics Unit, Public Health Wales NHS Trust, Cardiff CF14 4AY, UK
4 Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
5 Institute of Microbiology and Infection, University of Birmingham, Birmingham B15 2TT, UK
6 The COVID-19 Genomics UK (COG-UK) Consortium, https://www.cogconsortium.uk/
7 School of Biosciences, Cardiff University, Cardiff CF10 3AX, UK
8 MRC-University of Glasgow Centre for Virus Research (CVR), Glasgow G61 1QH, UK
9 Department of Zoology, University of Oxford, Oxford OX1 3SZ, UK
10 Department of Pathobiology and Population Sciences, The Royal Veterinary College, London AL9 7TA, UK
11 Lead contact
* Correspondence: ben.jackson@ed.ac.uk (B.J.), a.rambaut@ed.ac.uk (A.R.)

https://doi.org/10.1016/j.cell.2021.08.014

SUMMARY

We present evidence for multiple independent origins of recombinant SARS-CoV-2 viruses sampled from late 2020 and early 2021 in the United Kingdom. Their genomes carry single-nucleotide polymorphisms and deletions that are characteristic of the B.1.1.7 variant of concern but lack the full complement of lineage-defining mutations. Instead, the remainder of their genomes share contiguous genetic variation with non-B.1.1.7 viruses circulating in the same geographic area at the same time as the recombinants. In four instances, there was evidence for onward transmission of a recombinant-origin virus, including one transmission cluster of 45 sequenced cases over the course of 2 months. The inferred genomic locations of recombination breakpoints suggest that every community-transmitted recombinant virus inherited its spike region from a B.1.1.7 parental virus, consistent with a transmission advantage for B.1.1.7’s set of mutations.

INTRODUCTION

Recombination, the transfer of genetic information between molecules derived from different organisms, is a fundamental process in evolution, because it can generate novel genetic variation upon which selection can act (Felsenstein, 1974). Genetic analysis indicates that recombination occurs frequently in betacoronaviruses (Lai et al., 1985; Keck et al., 1988; Lai and Cavanagh, 1997), including natural populations of MERS-CoV (Corman et al., 2014; Dudas and Rambaut, 2016; Kim et al., 2016) and SARS and SARS-like coronaviruses (Hon et al., 2008; Boni et al., 2020). The zoonotic transmission of an alphacoronavirus whose spike gene shows evidence of being the product of recombination between feline and canine coronaviruses has occurred in Malaysia, which demonstrates the potential for coronavirus recombination associated with host reservoirs (Vlasova et al., 2021). It has been proposed recently that the global SARS-CoV-2 genome sequence data contain signals of recombination across the pandemic (VanInsberghe et al., 2021).

Recombination has the potential to be important in the context of pathogen evolution, because it can “rescue” genomes with otherwise deleterious mutations or provide the opportunity to create novel phenotypes by bringing genetic variation from different backgrounds onto a single genome. A concerning scenario from an epidemiological perspective is the potential for recombination to combine, in the same genome, mutations that may confer immune-escape properties with those that may enhance transmissibility. Enhanced transmissibility (Volz et al., 2021) and immune-escape (Planas et al., 2021) phenotypes have already been observed in SARS-CoV-2. Consequently, the characterization of recombination in SARS-CoV-2 is important for surveillance purposes.

The molecular mechanism of homologous recombination in unsegmented positive-sense RNA viruses such as SARS-CoV-2 is generally by copy-choice replication, a model first suggested in poliovirus (Copper et al., 1974). In this process, a hybrid or
mosaic RNA is formed when the RNA-polymerase complex switches from one RNA template molecule to another during replication (Worobey and Holmes, 1999). In order for homologous recombination to occur and be subsequently detected, there must be coinfection of the same cell within an individual by genetically distinct viruses (termed the “parental” lineages of the recombinant virus). Coinfection of an individual requires there to be co-circulation of multiple viral lineages within a population and, given the short duration of most SARS-CoV-2 infections, is most likely to be observed when virus prevalence is high.

Conditions conducive to SARS-CoV-2 recombination existed in the United Kingdom (UK) during the latter part of 2020 and early in 2021. From mid-October 2020 to January 2021, SARS-CoV-2 prevalence was estimated to be between 1% and 2% in England (Steel and Hill, 2021). During this time, the B.1.1.7 variant of concern (VOC), which is also referred to as alpha under the World Health Organization nomenclature (WHO (World Health Organization), 2021), emerged, rapidly increased in frequency, and spread across the UK, replacing lineages that were already at high prevalence (Volz et al., 2021). The most common of the latter was the B.1.177 lineage and its descendants (Hodcroft et al., 2021) (Figure 1). B.1.1.7 is characterized by an unusually large number of genetic changes (22 mutations from its immediate ancestor; (Rambaut et al., 2020b)). The ability to detect virus recombination using comparative sequence analysis depends on the genetic distinctiveness of the parental viruses, so the co-circulation of B.1.1.7 and non-B.1.1.7 viruses is expected to increase the power to detect recombinants between these lineages. The UK’s high rate of genomic surveillance and unified collection of genomic, epidemiological, and geographic data also provide multiple lines of evidence for evaluating the identification of recombinant viruses.

To identify putative SARS-CoV-2 recombinant viruses, we carried out an analysis of all complete UK SARS-CoV-2 genomes that had been assigned to lineage B.1.1.7 and that showed evidence of being the product of combining different genetic lineages, indicative of recombination. Specifically, we scanned the UK dataset for genomes that were alternately composed of long contiguous tracts of B.1.1.7 and non-B.1.1.7 genetic variation. The genetic composition and epidemiological context of each candidate mosaic genome was carefully explored to determine whether it was recombinant in origin. We subsequently determined whether the recombinants showed evidence of onward transmission within the UK population. One recombinant lineage continued to circulate for at least 9 weeks and, as of May 5, 2021, was associated with 45 linked infections.

RESULTS

Identification of putative recombinants

We identified a total of 16 recombinant sequences from the whole UK dataset of 279,000 sequences up to March 7, 2021 using our bioinformatic and evolutionary analysis pipeline (see STAR Methods). Twelve genome sequences that clustered into four groups (labeled A–D), and four additional singletons showed evidence of being mosaic in structure (Table 1; Table S1). For each group A–D, each of the constituent genomes was sampled from the same geographic locality within the UK (Table 1). For group A, which spanned two geographical regions, all the samples originated from close to the border between Wales and North West England (<20 km apart). The sample dates for the putative recombinants ranged from December 18, 2020 to February 2, 2021 (Figure 1). If groups A–D represent community transmission of a recombinant lineage with a single origin, recombination must have occurred on or before the date of the earliest sample in each group. It is possible to use molecular clock dating to infer bounds on recombination events, but given uncertainties in the rate of the molecular clock, estimates from such methods have large confidence intervals (Raghwani et al., 2012). Because our dataset consists of high-density genomic sampling covering the time period over which we infer recombination to have occurred, we use the earliest sample dates described above as representative of the approximate time of the recombination events. The range of dates coincides with a period of increasing relative prevalence of B.1.1.7 in the UK alongside the presence of other circulating lineages in the community, the most common of which were B.1.177 and its descendants (Figure 1).

To rule out the possibility that any of the 16 recombinants could have resulted from artifacts as a result of assembling
sequence reads from a co-infected sample (generated through either natural coinfection or laboratory contamination), we examined the read coverage and minor allele frequencies and assessed the likelihood of a mixed sample. Several lines of evidence suggested the recombinant sequences were not the products of sequencing a mixture of genomes. First, the sequencing protocol used in the UK (Tyson et al., 2020) generates 98 short (~350-bp) amplicons, such that long tracts that match just one lineage would be unlikely. Second, the read data do not support a mixture for any of the putative recombinant genomes. All the recombinants were sequenced to high coverage (lowest mean read depth per site per genome: 686; highest mean read depth: 2,903). The mean minor allele frequency (MAF) for the putative recombinants was 0.008, which is 6 standard deviations below the mean of the MAF (0.34) for a set of 20 sequences that we suspected to be mixtures (Figure S1). Finally, for all groups A–D, multiple genomes with the same mosaic structure were sequenced independently from different samples, and by different sequencing centers in the case of group A, implying that the original assembly was correct and, additionally, that transmission of the recombinant had occurred. All of the read data are available on the European Nucleotide Archive. Accession numbers are given in Table S2.

Epidemiological information supports the identification of putative parental lineages

The nucleotide variation for the putative recombinants and their closest neighbors by genetic similarity (for each of the regions of their genomes either side of the recombination breakpoint) is shown in Figures 2 and S2. For each of groups A–D, the closest neighbors by genetic similarity for each of the two non-recombinating genome regions were the same sequences for every putative recombinant within a group. For most of the recombinants, there were several equidistant putative parental sequences for each region of the genome; whenever this was true, they all belonged to the same lineage, except for group C, whose putative parental lineages for the non-B.1.1.7-like region of the genome were a mixture of two closely related lineages (B.1.221.1 and B.1.221.2). The putative parental sequence for the non-B.1.1.7 region of the genome varied by group (Table 1). Importantly, in each case, the sequence and epidemiological data demonstrate that the non-B.1.1.7 parental sequence was circulating in the same geographic area as the recombinant in the time immediately before the sampling date of the recombinant. For group A and the four singletons, the second parental sequence was assigned lineage B.1.177 or one of its descendants. B.1.177, which likely arose in Spain in the summer of 2020 and was exported to multiple European countries (Hodcroft et al., 2021), rose to high relative frequency in the UK through autumn 2020 and was widespread by December (Figure 1). Lineage B.1.177.16, the second parental sequence of MILK-103C712, was sampled 25 times in Greater London in the 4 weeks preceding MILK-103C712’s sample date. Lineage B.1.177.9 was sampled on one other occasion in Scotland in 4 weeks preceding QUEH-1067DEF’s sample date. Lineage B.1.36.28 was not sampled in South East England in the 4 weeks preceding group B’s sample date but was sampled eight times in Greater London in that period. Lineages B.1.221.1 and B.1.221.2 were sampled seven and zero times, respectively, in the East Midlands in the 4 weeks preceding group C’s sample date, and B.1.36.17 was sampled five times in the South East in the 4 weeks prior to group D’s sample date. The distributions of the most prevalent lineages in each

| Group | No. | Location                  | Sample dates (year/month/day) | Second parent lineage | Second parent date (year/month/day) | Second parent location | Breakpoint coordinates |
|-------|-----|---------------------------|------------------------------|-----------------------|------------------------------------|-----------------------|------------------------|
| A     | 4   | Wales/North West England  | 2021/01/30–2021/02/21        | B.1.177               | 2021/01/27                         | Wales                 | 21,255–21,765          |
|       |     |                           |                              |                       |                                    |                       | (20,410–21,765)a       |
| B     | 2   | South East England        | 2020/12/23–2020/12/24        | B.1.36.28             | 2020/12/10                         | Greater London        | 6,528–6,954            |
| C     | 3   | East Midlands (England)   | 2021/01/18–2021/01/30        | B.1.221.1 / B.1.221.2 | 2021/01/02                         | East Midlands/Greater London | 24,914–28,651         |
| D     | 3   | South East England        | 2021/02/02–2021/02/07        | B.1.36.17             | 2020/12/10                         | East of England       | 21,575–23,063          |
| CAMC-CBA018 | 1 | Greater London            | 2020/12/18                  | B.1.177               | 2021/01/23                         | UK                    | 11,396–21,991          |
| CAMC-CB7AB3 | 1 | Greater London            | 2020/12/18                  | B.1.177               | 2020/12/12                         | Greater London        | 3,267–6,286 and 12,534–21,765 |
| MILK-103C712 | 1 | Greater London            | 2021/01/12                  | B.1.177.16            | 2020/12/14                         | Greater London/East of England | 26,801–27,972         |
| QUEH-1067DEF | 1 | Scotland                  | 2021/01/17                  | B.1.177.9             | 2021/01/13                         | Greater London        | 6,954–10,870           |

The first parental lineage is always B.1.1.7. For the recombinant groups, the number of genomes, the NUTS1 location of residence, and the range of sampling dates are given. Breakpoint coordinates are the range of possible SARS-CoV-2 genome positions bounded by mutations that are unambiguously inherited from one parent or the other, including both single-nucleotide polymorphisms and deletions. The date and location for the second parent is for the genetically most similar UK genome(s) within the genome region belonging to that lineage.

*aFor group A, the results for LIVE-DFCFFE (in parentheses) were different from those of the rest of the group.*
region of the UK relevant to the eight sets of recombinants (groups A–D and the four singletons) for the 4 weeks immediately preceding the date of the earliest sampled genome in each case are shown in Figure S3.

**Putative recombinants exhibit significant mosaicism**

We rejected the null hypothesis of non-reticulate evolution for 14 out of the 16 putative recombinant sequences by testing these sequences for mosaicism (3SEQ; Lam et al., 2018; with Dunn-Sidak correction for multiple comparisons) against a background set of 2,000 sequences randomly drawn from the course of the UK epidemic (Table 2). The lineages identified as the putative parentals assigned by 3SEQ agreed with the lineages for putative parentals assigned by genetic similarity (Tables 1 and 2), even though of the 16 closest neighbors by genetic similarity described above, none were present in the background sequence set of candidate parentals used in the 3SEQ analysis. The breakpoints reported by 3SEQ also agreed with breakpoints inferred from the distribution of single-nucleotide polymorphisms (SNPs) and deletions in the putative recombinants and their neighbors by genetic similarity (Tables 1 and 2). The two sequences that belong to group B did not show a statistically significant mosaic signal of non-reticulate evolution, but 3SEQ’s $\Delta_{m,n,2}$ statistic for these two candidate recombinants showed the greatest support for mosaicism possible among the ancestry-informative polymorphic sites with their closest neighbors by genetic similarity (Tables 1 and 2). The two sequences that belong to group B did not show a statistically significant mosaic signal of non-reticulate evolution, but 3SEQ’s $\Delta_{m,n,2}$ statistic for these two candidate recombinants showed the greatest support for mosaicism possible among the ancestry-informative polymorphic sites with their closest neighbors by genetic similarity (Tables 1 and 2). The two sequences that belong to group B did not show a statistically significant mosaic signal of non-reticulate evolution, but 3SEQ’s $\Delta_{m,n,2}$ statistic for these two candidate recombinants showed the greatest support for mosaicism possible among the ancestry-informative polymorphic sites with their closest neighbors by genetic similarity (Tables 1 and 2).

The Dunn-Sidak correction used in 3SEQ is very conservative, as it assumes that all 64.0 million comparisons we performed are independent statistical tests, when in fact these tests are highly nonindependent, since many candidate parental sequences are a small number of nucleotide differences apart from each other. When corrected p values are borderline, the recommended approach to infer reticulate evolution is to build separate phylogenetic trees for the nonrecombining regions of the genome to confirm that the recombinant in question has different phylogenetic placements in different genomic regions (Boni et al., 2010). With the exception of the inner region for CAMC-CB7AB3, whose placement within B.1.177 was not well supported, each recombinant’s two phylogenetic placements were with the lineages that we identified as parental by genetic similarity and by using 3SEQ, with high bootstrap support (Table S3). The placement of the two parental genome regions for each recombinant in the context of the whole epidemic in the UK is shown in Figure 3.

The mosaic structures of the genomes of the putative recombinants are shown in Figure 4. In six out of eight instances (and all four of the groups of >1 sequence, which may represent community transmission), the recombinants contain a spike gene from the B.1.1.7 lineage. In four instances, there is a proposed recombination breakpoint at or near the 5’ end of the spike gene.

**Further evidence for the community transmission of group A**

A follow-up investigation of the eight sets of putative recombinants (groups A–D and the four singletons) on May 5, 2021 found 41 sequences that were descended from group A (Figure 5). No descendants from any other recombinant event were detected to have continued to circulate. The 41 sequences share the same set of SNPs with three members of group A (ALDP-11CF93B, ALDP-125C4D7, and LIVE-DFCFFE), with additional nucleotide variation at positions 8,090, 16,260, and 25,521 (Figures 5A and S4). They were sampled in North West England between March 1, 2021 and April 4, 2021 (Figures 5B and 5C). The temporal distribution of samples descended from the recombination event that led to group A suggests that the recombinant lineage persisted at low frequency for a period of time before expanding and then contracting again (Figure 5C). A second follow-up investigation on July 14, 2021 found no further recombinants descended from group A, which suggests that this transmission cluster is extinct. The dynamics of this cluster of infections reflect the wider trend of SARS-CoV-2 prevalence in England over the same time period. Prevalence decreased from a maximum of 2.08% in January 2021 to 0.21% for the week beginning April 4, 2021 and to <0.1% as of the beginning of May 2021 (Steel and Hill, 2021). Group A and its descendants met the criteria for designation as a recombinant Pango lineage (Pybus, 2021).
In Varabyou et al., 2020, there is generally little statistical support to reject the possibility that the sequence patterns could have been generated by mutation alone. In contrast, there is sufficient diversity in the UK virus dataset between the lineage B.1.1.7 and other co-circulating lineages to detect putative recombinants and demonstrate statistical significance for their breakpoints. Candidate recombinants and their parental lineages are a median of 22.5-nt mutations apart, and candidate pairs of parents are a median of 46-nt differences apart from each other (Figures 2 and S2). The p values we present are exact non-parametric probabilities that the observed patterns of nucleotide ancestry in the candidate recombinant viruses were generated by mutation alone given the parental genotypes and are corrected for multiple testing.

The breakpoint locations inferred from the recombinants’ parental lineages by two different methods and two different parental datasets are in agreement (cf. Tables 1 and 2). Two interesting observations arise from their distribution. First, in six cases, and in all the cases where we detected transmission, the spike gene was inherited from the B.1.1.7 parental sequence (Figures 2). This is consistent with the observed transmission advantage of B.1.1.7 (Volz et al., 2021), which is likely attributable to the mutations it carries in the spike region (Rambaut et al., 2020b). Second, in four instances, a breakpoint is located near the 5’ end of the spike gene. A defining feature of the order Nidovirales, to which coronaviruses belong, is the production during RNA synthesis of a set of nested positive- and negative-stranded subgenomic RNAs (sgRNAs) that contain a leader sequence derived from the 5’ end of the complete genome and a progressively reduced complement of the structural (S, E, M, N) and accessory genes, which form the body of the sgRNA molecule (Masters, 2006; Kim et al., 2020). The discontinuous nature of these sgRNAs is understood to be the product of template switching by viral polymerase during normal transcription, where the polymerase pauses at a transcription-regulatory sequence (TRS) after transcribing the last open reading frame (ORF) of the sgRNA and switches to a similar TRS upstream of the leader sequence (Sawicki and Sawicki, 1995), omitting a looped-out region of the template RNA, which contains at least orf1ab in the case of SARS-CoV-2 (Finkel et al., 2021). This provides an environment that is highly conducive to homologous recombination, including a polymerase that engages in template switching during its normal transcriptional activity and the availability of alternative template RNA molecules, in the form of sgRNAs, which incorporate sequence motifs that mediate template switching and might be derived from different genomes.

## DISCUSSION

Here, we report the first unambiguous detection and characterization of the arisal and subsequent community transmission of recombinant SARS-CoV-2 viruses. Comparison of intragenomic variation, supported by geographic and epidemiological data, demonstrates the occurrence of multiple independent recombination events involving UK virus lineages in late 2020. Recombinant genomes that share genetic identity were sampled from the same geographic location and time period, indicating they represent successful onward transmission after the occurrence of a single ancestral recombination event. In one instance, this resulted in a significant transmission cluster comprising 45 observed cases, which has been given the Pango lineage name XA. While no obvious biological advantage can be attributed to this cluster (or any of the observed recombinants) beyond the acquisition of B.1.1.7’s set of spike mutations, these recombinants are sentinel events for the spike gene was inherited from the B.1.1.7 parental sequence (Rambaut et al., 2020b). Second, in four instances, a breakpoint is located near the 5’ end of the spike gene. A defining feature of the order Nidovirales, to which coronaviruses belong, is the production during RNA synthesis of a set of nested positive- and negative-stranded subgenomic RNAs (sgRNAs) that contain a leader sequence derived from the 5’ end of the complete genome and a progressively reduced complement of the structural (S, E, M, N) and accessory genes, which form the body of the sgRNA molecule (Masters, 2006; Kim et al., 2020). The discontinuous nature of these sgRNAs is understood to be the product of template switching by viral polymerase during normal transcription, where the polymerase pauses at a transcription-regulatory sequence (TRS) after transcribing the last open reading frame (ORF) of the sgRNA and switches to a similar TRS upstream of the leader sequence (Sawicki and Sawicki, 1995), omitting a looped-out region of the template RNA, which contains at least orf1ab in the case of SARS-CoV-2 (Finkel et al., 2021). This provides an environment that is highly conducive to homologous recombination, including a polymerase that engages in template switching during its normal transcriptional activity and the availability of alternative template RNA molecules, in the form of sgRNAs, which incorporate sequence motifs that mediate template switching and might be derived from different genomes.

### Table 2. Recombinants, their putative second parental lineages, and inferred breakpoints according to 3SEQ

| Group | Second parent lineage | Uncorrected p value | Corrected p value | Breakpoint coordinates |
|-------|-----------------------|---------------------|-------------------|-----------------------|
| Group A | B.1.177 | 5E-13 (1E-12) | 0.00003 (0.00006) | 21,255–21,613 (18,998–20,294) |
| Group B | B.1.221.1 | 4.26E-10 | 0.02686 | 25,996–27,441 |
| Group D | B.1.36.39 | 3E-12 | 0.0002 | 20,703–23,062 |
| CAMC-CBA018 | B.1.177 | 2E-12 | 0.00014 | 20,389–21,254 |
| CAMC-CB7AB3 | B.1.177 | 1E-11 | 0.00065 | 3,267–4,474 and 20,389–21,254 |
| MILK-103C712 | B.1.177 | 1.06E-10 | 0.00673 | 408–444 and 26,801–27,876 |
| QEUH-1067DEF | B.1.177 | 4.12E-10 | 0.026 | 10523 – 10869 |

The first parental lineage is always B.1.1.7. p values for the Δ_m,n,2 statistic are reported uncorrected and after Dunn-Sidak correction for multiple comparisons.

*The breakpoint coordinates reported by 3SEQ are the positions of spaces between nucleotides.

*For group A, the results for LIVE-DFCFFE (in parentheses) were different from those of the rest of the group.

*Statistics are from a separate run with the closest neighbors by genetic similarity included in the parental dataset.

and have been named lineage XA (https://cov-lineages.org/lineages/lineage_XA.html).
in the case of coinfection. As TRSs, which occur between the ORFs (Kim et al., 2020), are important in mediating template switching during homologous recombination in coronaviruses, this can account for the shared pattern of recombination-prone regions observed here (Figure 4). However, to be detected, recombinant genomes must lead to viable viruses, so the distribution of breakpoints observed from genomic surveillance may not represent the distribution of breakpoints that occur in situ (Banner and Lai, 1991).

Given the overall prevalence of SARS-CoV-2 in the UK in December 2020 of 1% (Steel and Hill, 2021) and assuming that 40% of infections were of lineage B.1.1.7 and 40% of B.1.177 (Figure 1), a simplistic expectation for the number of coinfections involving these two lineages is the product of their prevalences, which is 16 coinfections per million people. The figure is 70 coinfections per million people for a prevalence of 2%, 70% infection with B.1.1.7, and 25% infection with B.1.177, which applies to the first half of January 2021. In this calculation, we assume that infections are independent and that once infected, the chance of an additional infection occurring is unchanged. This illustrates that on a national scale, coinfection should be quite common during periods of high prevalence. From a public health perspective, this reminds us that halving prevalence reduces the chance of coinfection by a factor of four, because the probability of coinfection increases with the square of the prevalence.

As recombination permits the combination of advantageous mutations from distinct variants and recombination is only possible with coinfection, minimizing the prevalence of SARS-CoV-2 will minimize the chance of forming recombinant lineages with genetic combinations that could potentially increase virus fitness. At the time of writing, the trajectory of the SARS-CoV-2 pandemic continues to remind us that there are many populations worldwide still highly susceptible to large epidemic waves. High-prevalence epidemic waves comprising diverse viral lineages risk high rates of meaningful recombination, and as SARS-CoV-2 genetic diversity is much greater in 2021 than in 2020, it will be important to examine each epidemic for the presence of novel recombinant lineages, especially epidemics occurring in regions with circulation of different variants of biological significance.
Limitations of study

In the Results, we discuss the possibility that the mosaic patterns of genetic variation observed in the putative recombinant genome sequences might be the product of some process other than recombination, for example the sequencing of a natural coinfection or of a mixed sample due to laboratory contamination. However, neither the distribution of the raw read allele frequencies for the putative recombinants (which are unlike those we observe in samples that we suspect to be real mixtures) nor the spatial distribution of genetic variation along their genomes (consisting of long contiguous tracts compatible with a single lineage, which is not the pattern expected for a mixture of samples given the sequencing protocol employed in the UK) suggests that this is the case. In the case of the groups A–D, the sequencing of multiple distinct samples with nearly identical genetic variation provides strong \textit{posteriori} evidence against any of these genomes being the product of sequencing a mixed sample. This strength of evidence does not exist for the four singleton genomes, so they should be viewed as less certainly recombinant.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- \textbf{KEY RESOURCES TABLE}
- \textbf{RESOURCE AVAILABILITY}
  - Lead contact
  - Materials availability
  - Data and code availability
- \textbf{METHOD DETAILS}
  - Identification of putative recombinants
  - Identification of candidate parental sequences
  - Defining a representative sample from the UK epidemic
  - Investigation of read data
- \textbf{QUANTIFICATION AND STATISTICAL ANALYSIS}
  - Test for mosaic genome structure

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.cell.2021.08.014.

CONSORTIA

The members of the COG-UK Consortium are Samuel C. Robson, Tanya Golubchi, Rocio T. Martinez Nunez, Catherine Ludden, Sally Corden, Ian Johnston, David Bonsall, Colin P. Smith, Ali R. Awan, Giselda Bucca, M. Esteve Torok, Kordo Saeed, Jacqui A. Prieto, David K. Jackson, William L. Hamilton, Luke B. Snel, Catherine Moore, Ewan M. Harrison, Sonia Goncalves, Leigh M. Jackson, Ian G. Goodfellow, Derek J. Fairey, Matthew W. Loose, Joanne Watkins, Samuel Moses, Roberto Amato, Joanne A. Prieto, David K. Jackson, Matthew T.G. Holden, Emma C. Thomson, Husam Osman, Monique Andersson, Rich Livett, Samuel C. Robson, Tanya Golubchi, Rocio T. Martinez Nunez, Catherine Ludden, Sally Corden, Ian Johnston, David Bonsall, Colin P. Smith, Ali R. Awan, Giselda Bucca, M. Esteve Torok, Kordo Saeed, Jacqui A. Prieto, David K. Jackson, William L. Hamilton, Luke B. Snel, Catherine Moore, Ewan M. Harrison, Sonia Goncalves, Leigh M. Jackson, Ian G. Goodfellow, Derek J. Fairey, Matthew W. Loose, Joanne Watkins, Samuel Moses, Roberto Amato, Ian R. Johnston, David Bonsall, Colin P. Smith, Ali R. Awan, Giselda Bucca, M. Esteve Torok, Kordo Saeed, Jacqui A. Prieto, David K. Jackson, William L. Hamilton, Luke B. Snel, Catherine Moore, Ewan M. Harrison, Sonia Goncalves, Leigh M. Jackson, Ian G. Goodfellow, Derek J. Fairey, Matthew W. Loose, Joanne Watkins, Samuel Moses, Roberto Amato, Joanne A. Prieto, David K. Jackson, Matthew T.G. Holden, Emma C. Thomson, Husam Osman, Monique Andersson, Rich Livett, Samuel C. Robson, Tanya Golubchi, Rocio T. Martinez Nunez, Catherine Ludden, Sally Corden, Ian Johnston, David Bonsall, Colin P. Smith, Ali R. Awan, Giselda Bucca, M. Esteve Torok, Kordo Saeed, Jacqui A. Prieto, David K. Jackson, William L. Hamilton, Luke B. Snel, Catherine Moore, Ewan M. Harrison, Sonia Goncalves, Leigh M. Jackson, Ian G. Goodfellow, Derek J. Fairey, Matthew W. Loose, Joanne Watkins, Samuel Moses, Roberto Amato, Darren L. Smith, Jeff Barrett, David M. Aanensen, Martin D. Curran, Surendra Parmar, Dinesh Aggarwal, James G. Shepherd, Matthew D. Parker, Sharon Glavsher, Matthew Bashton, Anthony P. Underwood, Katie F. Loveson, Alessandro M. Carabelli, Kate E. Templeton, Cordelia F. Langford, John Skillen, Thushan I. de Silva, Dennis Wang, Dominic Kwiakowski, Justin O’Grady, Simon Cottrell, Matthew T.G. Holden, Emma C. Thomson, Husam Osman, Monique Andersson, Anoop J. Chauhan, Mohammed O. Hassan-Ibrahim, Mara Laviniczak, Ravi Kumar Gupta, Alex Alderton, Meera Chand, Chrystala Constantinidou, Meera Unnikrishnan, Julian A. Hiscox, Steve Palmer, Inigo Martincorena, Erik M. Volz, Andrew J. Page, Andrew R. Bassett, Cristina V. Ariani, Michael H. Spencer Chapman, Kathy K. Li, Rajiv N. Shah, Natasha G. Jesudason, Yusri Taha, Martin P. McHugh, Rebecca Dewar, Aminu S. Jahun, Claire McMurray, Sarojini Pandey, James P. McKenna, Andrew Nelson, Gregory R. Young, Clare M. McCann, Scott Elliott, Hannah Lowe, Ben Temperton, Sunando Roy, Anna Price, Sara Rey, Matthew Wyles, Stefan Rooke, Sharif Shaaban, Mariateresa de Cesare, Laura Letchford, Siona Silveira, Emanuela Pelosi, Eleri Wilson-Davies, Myra Hoamilo, Andrew R. Hesketh, Richard Stark, Louis Di Plessis, Chris Ruis, Helen Adams, Yann Bourgeois, Stephen L. Michell, Dimitris Grammatopoulos, Jonathan Edgewort, Judith Breuer, John A. Todd, Christopher Fraser, David Bick, Michael John, Gemma L. Kay, Steve Palmer, Sharon J. Peacock, David Heyburn, Danni Weldon, Esther Robinson, Alan McNally, Peter Muir, Ian B. Hipwell, John Boyes, Venkat Sivaprakasam, Tranpri Salluja, Samir Dervic, Emma J. Meader, Naomi R. Park, Karen Oliver, Aaron R. Jeffries, Sashia Ott, Ana da Silva Filipe, David A. Simpson, Chris Williams, Jane A.H. Masoli, Bridget A. Knight, Christopher R. Jones, Cherian Koshy, Amy Ash, Anna Casey, Andrew Bosworth, Liz Ratcliffe, Li Xu-McCrae, Hannah M. Pyeont, Stephanie Hutchings, Lisa Berry, Katie Jones, Fenella Halstead, Thomas

Figure 4. Mosaicism of putative recombinants

Recombinant groups A–D contain multiple sequences exhibiting the same mosaic genome structures (see Table 1 for details). Tracts matching lineage B.1.1.7 are shown in blue, while virus genome regions matching other lineages are shown in yellow. Gaps represent ambiguity in the exact position of the recombinant breakpoints; there are no lineage-defining mutations within these regions. The breakpoint coordinates are taken from Table 1.
Figure 5. The community transmission of group A

(A) The phylogenetic relationships between the closest genetic neighbors of group A for the B.1.1.7-inherited region of their genome (top clade; left-hand tree) and the B.1.177-inherited region of their genome (bottom clade; left-hand tree), with branch lengths scaled by time. The sample date in cumulative epidemiological weeks (epiweeks) since the first epiweek of 2020 for each sequence is also represented by colored circles at the tips of each tree; see the key for this scale. The closest two parental sequences by genetic similarity for the two regions of the genomes (ALDP-12A277F and ALDP-119C5F7) are labeled in the left-hand tree, and their tips are highlighted by black rings. The phylogenetic relationships within group A (top four taxa) and their descendants (bottom 41 taxa) are shown in the right-hand tree, with branch lengths scaled by divergence. The dashed lines represent the formation of a new recombinant clade between the members of group A and their parental lineages.

(B) The geographic context of the transmitted recombinant sequences. The exploded region of the map is the North-West region of England. All of the 41 recombinants descended from group A were sampled in this region. The relative distribution of their locations, in the same scale as the exploded region, are represented by the circles in the red dashed square. The size of the points represents the number of genomes sequenced in each location. The absolute locations of the recombinants within North West England are not represented by this panel.

(C) The distribution of the sampling dates for the 45 recombinants, aggregated by epiweek. Orange bars, four original members of group A; green bars, 41 descendants from group A.
Kim S. Smith, Katerina Galai, Georgina M. McManus, Frances Bolt, Francesc Coll, Lizzie Meadows, Stephen W. Attwood, Alisha Davies, Elen De Lacy, Fatima Downing, Sue Edwards, Gary P. Scarlett, Sarah Jeremiah, Nikki Smith, Danielle Leek, Sushmita Sridhar, Sally Forrest, Clare Cormie, Harmeet K. Gill, Joana Dias, Ellen E. Higginson, Mallis Maes, Jamie Young, Michelle Wantoch, Sanger Covid Team (https://www.sanger.ac.uk/covid-team), Dorota Jamroz, Stephanie Lo, Minal Patel, Claire M. Bewshea, Sian Eillard, Cressida Auckland, Ian Harrison, Chloe Bishop, Vicki Chalker, Alex Richter, Alexander Beggs, Angus Best, Benita Percival, Jeremy Mirza, Oliver Megran, Megan Mayhew, Liam Crawford, Fiona Ashcroft, Emma Moleis-Garcia, Nicola Cumley, Richard Hopkins, Patawee Asamapahan, Marc O. Niebel, Rory N. Gunson, Amanda Bradley, Alasdair Maclean, Guy Mollett, Rebecca Blacow, Paul Bird, Thomas Helmer, Karlie Fallon, Julian Tang, Antony D. Hale, Louissa R. Macfarlane-Smith, Katharina L. Harper, Holli Carden, Nicholas W. Machin, Kathryn A. Jackson, Shaazad S.Y. Ahmad, Ryan P. George, Lance Turtle, Elaine O’Toole, Joanne Watts, Cassie Breen, Angela Cowell, Adeela Alcolea-Medina, Themoula Charalampous, Amita Patel, Lisa J. Levett, Judith Heaney, Aileen Rowan, Graham P. Taylor, Divya Shah, Laura Atkinson, Jack C.D. Lee, Adam P. Westhorpe, Riaz Jannoo, Helen L. Lowe, Angeliki Karamani, Leah Ensell, Wendy Chatterton, Monika Psuok, Ashok Dadrah, Amanda Symmonds, Graciela Sluga, Zoltan Molnar, Paul Baker, Stephen Bonner, Sarah Essex, Edward Barton, Debra Pгадett, Garren Scott, Jane Greenaway, Brendan A.I. Payne, Shirelle Burton-Fanning, Sheila Waugh, Veena Raviprakash, Nicola Sheriff, Victoria Blakey, Lesley-Anne Williams, Jonathan Moore, Susanne Stonehouse, Louise Smith, Rose K. Davidson, Luke Bedford, Lindsay Coupland, Victoria Wright, Joseph G. Chappell, Theocharis Tsieridis, Jonathan Ball, Manjinder Khakh, Vicki M. Fleming, Michelle M. Lister, Hannah C. Howson-Well, Louise Berry, Tim Boswell, Amelia Joseph, Iona Willingham, Nichola Duckworth, Sarah Walsh, Emma Wise, Nathan Moore, Matteo Morì, Nick Cortes, Stephen Kidd, Rebecca Williams, Laura Gifford, Kelly Bicknell, Sarah Wylie, Allyson Lloyd, Robert Impey, Cassandra S. Malone, Benjamin J. Cogger, Nick Levene, Lynn Monaghan, Alexander J. Keeley, David G. Partridge, Mohammad Raza, Cariad Evans, Kate Johnson, Emma Betteridge, Ben W. Farr, Scott Goodwin, Michael A. Quail, Carol Scott, Lesley Shirley, Scott A.J. Thurston, Diana Rajan, Iraad F. Bronner, Louise Aigrain, Nicholas M. Redshaw, Stefanie V. Lensing, Shane McCarthy, Alex Makunin, Carlos E. Balcazar, Michael D. Gallagher, Kathleen A. Williamson, Thomas D. Stanton, Michelle L. Michelson, Joanna Warwick-Dugdale, Robin Manley, Audrey Farbos, James W. Harrison, Christopher M. Sambles, David J. Studholme, Angie Lackenby, Tamyo Mibasa, Steven Platt, Shahjahan Miah, David Bibby, Carmen Mansoo, Jonathan Hubb, Gavin Dabrerara, Mary Ramsay, Daniel Bradshaw, Ulf Schaefer, Natalie Groves, Eileen Gallagher, David Lee, David William, Nicholas Ellaby, Hassan Hartman, Nikos Manesis, Vineet Patel, Juan Ledesma, Katherine A. Twogood, Elias Allen, Clare Pearson, Jeffrey K.J. Cheng, Hannah E. Bridgewater, Lucy R. Frost, Grace Taylor-Joyce, Paul E. Brown, Lily Tong, Alice Broos, Daniel Mair, Jenna Nichols, Stephen N. Carmichael, Katherine L. Smollett, Kyriaki Nomikou, Elhui Aranday-Cortes, Natasha Johnson, Seema Nikbaksh, Edith E. Vamos, Margaret Hughes, Lucille Rainbow, Richard Eccles, Charlotte Nelson, Richard Gregory, Matthew Gemmell, Chloé L. Fisher, Adrian W. Signell, Gilberto Betancor, Harry D. Wilson, Gaia Nebbia, Flavia Flaviani, Alberto C. Cerda, Tammy V. Merrill, Rebekah E. Wilson, Marius Cotic, Nadia Bayzid, Thomas Thompson, Erwan Acheson, Steven Rushton, Sarah O’Brien, David J. Baker, Stephen Rudder, Alp Aydin, Fei Sang, Johnny Debebe, Sarah Francois, Tetyana I. Vasyleva, Marina Escalera Zamudio, Bernardo Gutierrez, Angela Marchbank, Joshua Maksimovic, Karla Speliman, Kathryn McCluggage, Mari Morgan, Robert Beer, Safiah Afifi, Trudy Workman, William Fuller, Catherine Bresner, Adrienn Angyal, Luke R. Green, Paul J. Parsons, Rachel M. Tucker, Rebecca Brown, Max Whiteley, James Bonfield, Christof Papouts, Andrew Whitwham, Jennifer Liddle, Will Rowe, Igor Siveroni, Thanh Le-Viet, Amy Gaskin, and Rob Johnson.

ACKNOWLEDGMENTS

The authors thank two anonymous reviewers for comments on the manuscript. The COG-UK Consortium is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) (MC_PC_19027), and Genome Research Limited, operating as the Wellcome Sanger Institute. O.G.P. was supported by the Oxford Martin School. J.T.M., R.M.C., N.J.L., and A.R. acknowledge the support of the Wellcome Trust (Collaborators Award 206298/2/17/2 – ARTIC network). D.L.R. acknowledges the support of the MRC (MC_UU_12014/12) and the Wellcome Trust (220977/Z/20/2). E.S. and A.R. are supported by the European Research Council (grant agreement no. 725422 – ReservoirDOCS). T.R.C. and N.J.L. acknowledge the support of the MRC, which provided the funding for the MRC CLIMB infrastructure used to analyze, store, and share the UK sequencing dataset (MR/L015080/1 and MR/T030062/1). The samples sequenced in Wales were sequenced partly using funding provided by the Welsh Government.

AUTHOR CONTRIBUTIONS

Conceptualization, A.R., M.F.B., O.G.P., and B.J.; data curation, M.J.B., N.P., R.M.C., A.C., A.C.D., S.H., A.L., N.P., F.T., H.J.W., M.W., and C.W.; formal analysis, B.J.; interpretation, A.R., M.F.B., O.G.P., and J.T.M.; funding acquisition, A.R., T.R.C., N.J.L., O.G.P., and A.C.D.; resources, T.R.C., S.M.N., R.P., N.J.L., and R.M.C.; software, M.F.B., A.O.T., E.S., B.J., and M.W.; visualization, B.J., A.O.T., and V.H.; writing – original draft, B.J., M.F.B., O.G.P., and A.R.; D.L.R.; writing – review and editing, all authors.

DECLARATION OF INTERESTS

The authors declare no competing interests.

INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as living with a disability. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: June 16, 2021
Revised: July 29, 2021
Accepted: August 11, 2021
Published: August 17, 2021

REFERENCES

Banner, L.R., and Lal, M.M. (1991). Random nature of coronavirus RNA recombination in the absence of selection pressure. Virology 185, 441–445.
Boni, M.F., Posada, D., and Feldman, M.W. (2007). An exact nonparametric method for inferring mosaic structure in sequence triplets. Genetics 176, 1035–1047.
Boni, M.F., de Jong, M.D., van Doorn, H.R., and Holmes, E.C. (2010). Guidelines for identifying homologous recombination events in influenza A virus. PLoS ONE 5, e10434.
Boni, M.F., Lemey, P., Jiang, X., Lam, T.T.Y., Perry, B.W., Castoe, T.A., Rambaut, A., and Robertson, D.L. (2020). Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. 5, 1408–1417.
COG-UK (COVID-19 Genomics UK) (2020). An integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe 1, e99–e100.
Corman, V.M., Ithete, N.L., Richards, L.R., Schoeman, M.C., Preiser, W., Drosten, C., and Drexler, J.F. (2014). Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterisation of a conspécifique virus from an African bat. J. Virol. 88, 11297–11303.
Dudas, G., and Rambaut, A. (2016). MERS-CoV recombination: implications about the reservoir and potential for adaptation. Virus Evol. 2, vev023.
Feinstein, J. (1974). The evolutionary advantage of recombination. Genetics 78, 737–756.
Finkel, Y., Mizrahi, O., Nachshon, A., Weingarten-Gabbay, S., Morgenstern, D., Yahalom-Ronen, Y., Tamir, H., Achdout, H., Stein, D., Israel, O., et al. (2021). The coding capacity of SARS-CoV-2. Nature 589, 125–130.

Hoang, D.T., Chernomor, O., von Haeseler, A., Minh, B.Q., and Vinh, L.S. (2018). UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol. Biol. Evol. 35, 518–522.

Hodcroft, E.B., Zuber, M., Nadeau, S., Vaughan, T.G., Crawford, K.H.D., Althaus, C.L., Reichmuth, M.L., Bowen, J.E., Walls, A.C., Corti, D., et al.; Seq-COVID-SPAIN consortium (2021). Spread of a SARS-CoV-2 variant throughout Europe in the summer of 2020. Nature 595, 707–712.

Hon, C.-C., Lam, T.-Y., Shi, Z.-L., Drummond, A.J., Yip, C.-W., Zeng, F., Lam, P.-Y., and Leung, F.C.-C. (2008). Evidence of the recombination origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J. Virol. 82, 1819–1826.

Keck, J.G., Matsushima, G.K., Makino, S., Fleming, J.O., Vannier, D.M., Stohlm, S.A., and Lai, M.M. (1988). In vivo RNA-RNA recombination of coronaviruses in mouse brain. J. Virol. 62, 1810–1813.

Kim, J.J., Kim, Y.-J., Lemey, P., Lee, I., Park, S., Bae, J.-Y., Kim, D., Kim, H., Jang, S.-I., Yang, J.-S., et al. (2016). The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination. Rep. Seq. 6, 18825.

Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J.W., Kim, V.N., and Chang, H. (2020). The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914–921.e10.

Lai, M.M., and Cavanagh, D. (1997). The Molecular Biology of Coronaviruses. In Advances in Virus Research, K. Maramorosch, F.A. Murphy, and A.J. Shatkin, eds. (Academic Press), pp. 193–292.

Lai, M.M., Baric, R.S., Makino, S., Keck, J.G., Egbert, J., Leibowitz, J.L., and Stohlm, S.A. (1985). Recombination between nonsegmented RNA genomes of murine coronaviruses. J. Virol. 56, 449–456.

Lam, H.M., Ratmann, O., and Boni, M.F. (2018). Improved Algorithmic Complexity for the 3SEQ Recombination Detection Algorithm. Mol. Biol. Evol. 35, 247–251.

Li, H. (2018). Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100.

Li, H., Handsaker, B., Wysocky, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.: 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMTools. Bioinformatics 25, 2078–2079.

Lythege, K.A., Hall, M., Ferretti, L., de Cesare, M., MacIntyre-Cockett, G., Trebes, A., Andersson, M., Otecko, N., Wise, E.L., Moore, N., et al.; Oxford Virus Sequencing Analysis Group (OVSG); COVID-19 Genomics UK (COG-UK) consortium (2021). SARS-CoV-2 within-host diversity and transmission. Science 372, eabg0821.

Masters, P.S. (2006). The Molecular Biology of Coronaviruses. In Advances in Virus Research, K. Maramorosch, ed. (Academic Press), pp. 193–292.

Minh, B.Q., Nguyen, M.A.T., and von Haeseler, A. (2013). Ultrafast approxima-
tion for phylogenetic bootstrap. Mol. Biol. Evol. 30, 1188–1195.

Minh, B.Q., Schmidt, H.A., Chernomor, O., Schrempf, D., Woodhams, M.D., von Haeseler, A., and Lanfear, R. (2020). IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol. Biol. Evol. 37, 1530–1534.

O’Toole, Á., Scher, E., Underwood, A., Jackson, B., Hill, V., McCrone, J.T., Colquhoun, R., Ruis, C., Abu-Dahab, K., Taylor, B., et al. (2021). Assignment of Epidemiological Lineages in an Emerging Pandemic Using the Pangolin Tool. Virus Evol., veab064.

Plas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M.M., Bishop, E., et al. (2021). Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917–924.

Pybus, O.G. (2021). Pango Lineage Nomenclature: provisional rules for naming recombinant lineages. https://virological.org/t/pango-lineage-nomenclature-provisional-rules-for-naming-recombinant-lineages/657.

Raghwani, J., Thomas, X.V., and Koekkoek, S.M. (2012). Origin and Evolution of the Unique Hepatitis C Virus Circulating Recombinant Form 2k/1b. J. Virol. 86, 2212–2220.

Rambaut, A., Holmes, E.C., O’Toole, Á., Hill, V., McCrone, J.T., Ruis, C., du Plessis, L., and Pybus, O.G. (2020a). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407.

Rambaut, A., Loman, N.J., Pybus, O.G., Barclay, W., Barrett, J.C., Carabelli, A., and Robertson, D.L. (2020b). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.

Sagulenko, P., Puller, V., and Neher, R.A. (2018). TreeTime: Maximum-likelihood phylogeny analysis. Virus Evol. 4, vex042.

Sawicki, S.G., and Sawicki, D.L. (1995). Coronaviruses use Discontinuous Extension for Synthesis of Subgenome-Length Negative Strands. In Coronaviruses and Related Viruses: Current Concepts in Molecular Biology and Pathogenesis, P.J. Taibot and G.A. Levy, eds. (Springer US), pp. 499–506.

Steel, K., and Hill, T. (2021). Coronavirus (COVID-19) Infection Survey (England: Office for National Statistics). https://www.ons.gov.uk/peoplepopulationandcommunity/healthanddisability/datasets/coronaviruscovid19infectionsurveydata.

Tyson, J.R., James, P., Stoddart, D., Sparks, N., Wickenhagen, A., Hall, G., Choi, J.H., Lapointe, H., Kamelain, K., Smith, A.D., et al. (2020). Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. 1101/2020.09.04.283077.

VanInsberghe, D., Neish, A.S., Lowen, A.C., and Koelle, K. (2021). Recombinant SARS-CoV-2 genomes are currently circulating at low levels. bioRxiv. https://doi.org/10.1101/2020.08.05.238386.

Varabyou, A., Pockrandt, C., Salzberg, S.L., and Pettea, M. (2020). Rapid detection of inter-clade recombination in SARS-CoV-2 with Bololate. bioRxiv. https://doi.org/10.1101/2020.09.21.300913.

Vlasova, A.N., Diaz, A., Damtie, D., Xiu, L., Toh, T.-H., Lee, J.-s.Y., Saif, L.J., and Gray, G.C. (2021). Novel Canine Coronavirus Isolated from a Hospitalized Pneumonia Patient, East Malaysia. Clin. Infect. Dis., ciab456.

Volz, E., Mishra, S., Chard, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon, D.J., Dabreara, G., O’Toole, Á., et al.; COVID-19 Genomics UK (COG-UK) consortium (2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266–269.

WHO (World Health Organization) (2021). Tracking SARS-CoV-2 variants, accessed 4 August 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

Worobey, M., and Holmes, E.C. (1999). Evolutionary aspects of recombination in RNA viruses. J. Gen. Virol. 80, 2535–2543.
**STAR METHODS**

**KEY RESOURCES TABLE**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Deposited data      |        |            |
| Virus genome sequencing data | European Nucleotide Archive | See Table S2 |
| Software and algorithms |        |            |
| Grapevine           | Github repository | https://github.com/COG-UK/datapipe |
| type_variants       | Github repository | https://github.com/cov-ert/type_variants |
| gofasta             | Github repository | https://github.com/cov-ert/gofasta |
| snipit              | Github repository | https://github.com/aineniamh/snipit |
| Sequecing coverage  | Volz et al. (2021) | https://github.com/robj411/sequencing_coverage |
| Samtools            | Li et al. (2009) | https://github.com/samtools/samtools |
| 3SEQ                | Lam et al. (2018) | https://mol.ax/software/3seq/ |
| IQtree              | Minh et al. (2020) | http://www.iqtree.org/ |
| TreeTime            | Sagulenko et al. (2018) | https://github.com/neherlab/treetime |

**RESOURCE AVAILABILITY**

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ben. Jackson@ed.ac.uk.

**Materials availability**
This study did not generate new unique reagents.

**Data and code availability**
All the code used to perform the analyses here is available at: https://github.com/COG-UK/UK-recombination-analysis

**METHOD DETAILS**

**Identification of putative recombinants**
A national SARS-CoV-2 sequencing effort in the UK, the COG-UK consortium (COVID-19 Genomics UK (COG-UK (COVID-19 Genomics UK), 2020), has undertaken systematic genomic surveillance of SARS-CoV-2 in the country and generated over 440,000 genomes to date. As part of the COG-UK daily analytical pipeline (https://github.com/COG-UK/datapipe), the consensus genome sequences of the complete set of UK samples were aligned to the SARS-CoV-2 reference sequence (GenBank: MN908947.3) using Minimap2 (Li, 2018). The aligned sequences were converted from sam to fasta format, and each assigned a Pango lineage (Rambaut et al., 2020a) using Pangolin (O’Toole et al., 2021). Pango lineages are designed to capture ongoing epidemiological trends at a resolution suitable for genomic epidemiology and outbreak investigation (Rambaut et al., 2020a). From the sequence alignment, we extracted all sequences that had been assigned to lineage B.1.1.7, up to the 2021/03/07. We genotyped these sequences at the set of 22 sites that discriminate B.1.1.7 from its parental lineage (B.1.1) using a custom script in Python (https://github.com/cov-ert/type_variants), then discarded sequences with missing data at any of the 22 sites. We visualized the resulting table of genotype calls in order to identify sequences that showed evidence of a potential mosaic genome structure (i.e., runs of contiguous sites that were not compatible with the B.1.1.7 lineage designation).

**Identification of candidate parental sequences**
To identify candidate parental genome sequences in a computationally-tractable manner we created a set of all UK SARS-CoV-2 sequences that (i) contained no N nucleotide ambiguity codes after masking the 3’ and 5’ UTRs, (ii) spanned the dates 2020/12/01 to 2021/02/28, which represents two weeks before the date of the earliest putative recombinant, to one week after the date of the latest, and (iii) excluded the putative recombinant genomes identified above. This set consisted of 98859 sequences in total. For each putative recombinant, we split its genome sequence into B.1.1.7-like regions and non-B.1.1.7 regions at the junction of genetic regions according to the mosaic structure detected by the custom Python script described above (https://github.com/cov-ert/...
type_variants; Table S1). Then for each component region of each mosaic genome, we first masked the remainder of the genome with Ns (in both the focal mosaic sequence and all background sequences) then found the most-genetically similar non-focal sequences by computing pairwise genetic distances (number of nucleotide differences per site) using gofasta (https://github.com/cov-eri/gofasta). Subsequently, an alignment was compiled for each putative recombinant, which contained the putative recombinant as well as the most-genetically similar background sequences (as identified above) for each component region of that mosaic genome. The single nucleotide differences between the putative recombinant and the closely related reference sequences were visualized using snipit (https://github.com/aineniamh/snipit). The genomic coordinates of the boundaries between each mosaic genome region were then refined by taking into account observed lineage-defining nucleotide and deletion variation. Specifically, we set the boundary coordinates to the ends of sequential tracts of mutations specific to the putative parental sequences. This is a conservative approach to assigning parental lineages and consequently no parental lineage is assigned to those genome regions that do not contain unambiguous lineage-defining mutations or deletions. Lastly, using these refined region boundaries, we reiterated the genetic distance calculation above to identify a final set of most-genetically similar sequences for each putative recombinant.

When reporting geographic locations for UK virus genome sequences we use level 1 of the Nomenclature of Territorial Units for Statistics (NUTS) geocode standard (https://ec.europa.eu/eurostat/web/nuts/history).

Defining a representative sample from the UK epidemic
To generate a limited set of genomes that are suitable for computationally-expensive analysis yet are also representative of the genetic diversity of the SARS-CoV-2 epidemic in the UK, we randomly sampled 2000 sequences from 21st March 2020, when sequence data first became available, to 1st March 2021, weighting the probability of choosing a sequence accounting for the sequencing coverage and covid19 prevalence in individual geographic regions of the UK over time, using the same method as in Volz et al. (2021), which is available at (https://github.com/robj411/sequencing_coverage). We use this dataset to investigate the phylogenetic placement of the alternate regions of recombinant genomes, and as a dataset of putative parental sequences to statistically test for recombination using 3SEQ.

Investigation of read data
Almost all sequencing sites in the COG-UK consortium use the ARTIC PCR protocol to produce tiled PCR amplicons, which are then sequenced (Tyson et al., 2020). The generated sequence reads are then processed using sequence mapping, rather than sequence assembly, to produce a consensus genome for each sample. This approach, which was designed to support epidemiological investigations, creates a single consensus sequence for each sample. Beyond representing sites with high minor allele frequencies using the appropriate IUPAC nucleotide alphabet ambiguity code, this consensus does not reflect the natural genetic variation of SARS-CoV-2 genomes observed within an infected individual (Lythgoe et al., 2021). Mapping is particularly suited to tiled amplicons generated from samples that contain limited genomic diversity. Further, mapping is typically less prone to introducing errors/artifacts than sequence assembly and enables effective primer sequence removal and identification of non-reference mutations. Genomic sites that exhibit intra-sample nucleotide variation could be consistent with a range of processes, including co-infection, within-patient diversity, contamination, or PCR error. The identification of such sites forms part of the consensus-generating pipeline, and we exploit that information here in order to rule out the possibility that our mosaic consensus sequence represents a mixture of virus genomes, rather than representing true recombinant genomes.

For each putative recombinant sequence we analyzed the original read data from virus genome sequencing in order to rule out the possibility that the generated consensus sequence represents a mixture of virus genomes (due to laboratory contamination or coinfection, for example), rather than representing a true recombinant genome. To do this we calculated minor allele frequencies (MAFs) from the read data and compared their distribution between the 16 recombinant genomes and 20 samples that we suspected of being the product of sequencing a mixture of genomes, potentially because of coinfection or laboratory contamination. To define sequences that we suspected of being mixtures, we scanned the dataset for consensus sequences that possessed an IUPAC ambiguity code at the 27 genomic positions that differ from the SARS-CoV-2 reference genome (GenBank: MN908947.3) by a nucleotide change in B.1.1.7 (the 27 positions include those with nucleotide changes that were inherited from the ancestor of B.1.1.7). We define the MAF at a single site as the number of sequencing reads not containing the most frequently observed single nucleotide allele that mapped to that site, divided by the total number of sequencing reads that include any nucleotide allele that mapped to that site. For each virus genome, we defined a set of genomic positions from which to calculate MAF as follows. For each recombinant, we considered every site that differed from MN908947.3 by a nucleotide in its own consensus genome, or in the consensus genome of either of its parentals by genetic similarity. For the sequences that we suspected of being mixtures we considered the 27 genomic positions where sequences belonging to B.1.1.7 differ from MN908947.3 by a nucleotide change. We used samtools (Li et al., 2009), with default filters for mapping and base quality, to extract allele calls from the read data using its mpileup subroutine, and to calculate mean read depth per genome using its depth subroutine.

QUANTIFICATION AND STATISTICAL ANALYSIS

Test for mosaic genome structure
We used 3SEQ (Lam et al., 2018) as a statistical test for recombination in the UK SARS-CoV-2 data. 3SEQ interrogates triplets of sequences for a signal of mosaicism in one “child” sequence, given the genotypes of the other two “parental” sequences, using
an exact non-parametric test for clustering in a sequence of binary outcomes (Boni et al., 2007). The test statistic $D_{m,n,2}$ used in 3SEQ simply tests if a putative recombinant’s ancestry in parental A clusters in the middle of the genome, while ancestry in parental B clusters in the outer regions of the genome. We manually adjusted two-breakpoint recombinants to be single-breakpoint recombinants if one of the breakpoints according to 3SEQ abutted the beginning or end of the genome. We tested all potential pairs of sequences from the representative parental dataset from the course of the UK pandemic ($n = 2000$) against each putative recombinant in the child dataset ($n = 16$), and report $p$ values that are uncorrected and that are Dunn-Sidak corrected for multiple comparisons ($n = 64.0$ million). We performed a single additional run of 3SEQ with two putative recombinant sequences that were not found to be significantly the mosaic product of any of the sequences in the representative background as children, and their closest neighbors by genetic similarity as parents. $P$ values for this test were reported without correction and after correction for multiple testing assuming that this test was in addition to the 64 million comparisons that we had already performed. The input and output files for the 3SEQ analysis are available at https://github.com/COG-UK/UK-recombination-analysis.

**Test for the phylogenetic incongruence of putative recombinant genome tracts**

For each of the eight sets of recombinants (Groups A-D and the four singletons) we carried out the following procedure to test for incongruence between the phylogenetic placements of the two regions of their genomes. We independently added each set’s genome(s) to the representative background of 2000 sequences, along with the reference sequence, to create eight alignments in total. We masked the resulting alignments according to the breakpoints defined by the closest neighbors by genetic similarity, so that for each set, we produced two sub-alignments: one consisting of the region that was inherited from the B.1.1.7 parental in the recombinant(s), and one consisting of the region that was inherited from the other parental. This resulted in 16 alignments in total. We reconstructed the phylogenetic relationships for each with IQTREE v2.1 (Minh et al., 2020), using the HKY model of nucleotide substitution, conducting 1000 ultrafast bootstrap replicates (Minh et al., 2013; Hoang et al., 2018), and rooting the tree on the reference sequence, which is basal to all B lineage sequences. The phylogenetic trees produced by this analysis are available at https://github.com/COG-UK/UK-recombination-analysis.

To determine the placement of the different regions of each recombinant genome in a single context, we also built a phylogenetic tree of the representative background’s complete genomes, to which we added the masked recombinant genomes, so that each recombinant was present in the alignment twice, once with the B.1.1.7 region of its genome unmasked, and once with the opposing region unmasked. We ran IQTREE as above.

**Follow up of putative recombinants**

To test for onward community transmission of the putative recombinants, we searched the whole UK dataset as of the 5th May 2021 for additional sequences whose genetic variation matched the variation of the recombinants. For each of the eight set of recombinants, we defined a set of SNPs and deletions by which all the recombinants within that set differed from the reference sequence (MN908947.3). Then we used type_variants to scan the UK dataset for genomes whose SNP and deletion variation was compatible with being a descendant or sibling of the putative recombinants. Group A represented the only recombination event with evidence for further transmission according to the results of this procedure. We carried out the following additional analyses to further investigate transmission of Group A genomes. First, we visualized the nucleotide variation of the additional matching genomes using snipit and extracted their sampling locations and dates. Second, to explore the phylogenetic context of Group A and its derivatives, we reconstructed their (whole-genome) phylogenetic relationships using IQTREE. We also extracted the 100 closest sequences by genetic similarity for each alternate region of the genome (B.1.1.7-like and non-B.1.1.7-like) for each of the four original members of Group A to provide phylogenetic context to the parental sequences. This resulted in a dataset of 216 sequences in total when the two groups of neighbors were combined, and duplicates removed. We reconstructed their (whole-genome) phylogenetic relationships with the IQTREE, as above. We generated a time-scaled phylogenetic tree from the divergence tree of parental sequences using TreeTime (Sagulenko et al., 2018), setting the–clock-rate parameter to 0.001. We labeled the phylogenetic tree of recombinants and the phylogenetic tree of parental sequences with the sampling data in number of epidemiological weeks (epiweeks) since the first epiweek of 2020 to assess the temporal context of the recombination event and subsequent transmission. We carried out a second follow up on 14th July 2021 using the same procedure as above.
Figure S1. Read data minor allele frequencies, related to STAR Methods
The distribution of minor allele frequencies from the read data for the 16 putative recombinants (red bars) and 20 samples suspected of being sequenced mixtures, either due to co-infection or laboratory contamination (gray bars). For each recombinant, the minor allele frequency is the mean across all sites that differ by a nucleotide change from the reference (MN908947.3) in it or either of its putative parentals by genetic similarity. For the mixtures, the minor allele frequency is the mean across the sites that differ by a nucleotide change from the reference at genomic positions where mutations occur in B.1.1.7.
Figure S2. The nucleotide variation present in the recombinants and their parentals, related to Figure 2
The nucleotide variation with respect to the reference sequence (MN908947.3; gray genome far bottom) for each of the recombinant genomes (middle colored genomes in each panel) and their closest neighbors by genetic similarity among all UK sequences from the same time period, for the B.1.1.7-like and non-B.1.1.7-like regions of their genomes (top and bottom colored genomes in each panel).
(A) Group B.
(B) Group C.
(C) Group D.
(D) CAMC-CBA018.
(E) CAMC-CB7AB3.
(F) MILK-103C712.
(G) QEUH-1067DEF.
Figure S3. SARS-CoV-2 lineages in geographic regions of the UK relevant to the recombinants, related to Figure 1

The distribution of the most frequent SARS-CoV-2 lineages in the NUTS1 location of each set (Groups A-D and the four singletons) of recombinants for the four weeks immediately preceding each set’s (earliest) sample date. Here, B.1.177 refers to B.1.177 itself and all its descendant lineages (e.g., B.1.177.9); the same is true for B.1.36.
Figure S4. The nucleotide variation present in the descendants of group A, related to Figure 5

The distribution of nucleotide variation in the original members of group A (top four colored rows) and the 41 additional sequences that are derived from it (bottom 41 colored rows), with respect to the reference sequence (MN908947.3; very bottom gray sequence).